Key result
Maternal administration of digoxin successfully maintained normal fetal heart rate for three weeks, allowing safe delivery at 37 weeks gestation in a fetus with supraventricular tachycardia and hydrops.
Why the study?
Does maternal administration of digoxin improve outcomes in a fetus with supraventricular tachycardia and fetal hydrops?
Case Report (n=1)
Does maternal administration of digoxin improve outcomes in a fetus with supraventricular tachycardia and fetal hydrops?
Maternal administration of digoxin can effectively treat fetal supraventricular tachycardia with hydrops and safely prolong pregnancy.
May support maternal digoxin to prolong select fetal SVT pregnancies; leaves open need for controlled trials.
We present a special case of fetal supraventricular tachycardia detected at 34 weeks gestation. Fetal hydrops was noted on ultrasound upon admission. Normal fetal heart rate was maintained for three weeks by maternal administration of digoxin. A live infant was delivered via caesarian section at 37 weeks gestation. This clinical case demonstrated that pharmacological treatment can be effective and helps to prolong pregnancy safely.
No takes yet. Share an insight, caveat, or question.
Mačiulevičiūtė et al. (2020) conducted a case report in Fetal supraventricular tachycardia and fetal hydrops (n=1). Digoxin was evaluated on Maintenance of normal fetal heart rate and prolongation of pregnancy. Maternal administration of digoxin successfully maintained normal fetal heart rate for three weeks, allowing safe delivery at 37 weeks gestation in a fetus with supraventricular tachycardia and hydrops.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: